Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Cannabotech technology eliminated 90%-plus of colon cancer cells in cell model

Closely held Cannabotech of Israel reports that its cell model study results have shown that its integrative colon products killed more than 90% of colon cancer cells in a cell model experiment. The integrative colon...

March 7, 2022

Developments

Altamira, Nuance in pact to distribute Bentrio in China, other Asian markets

Altamira Therapeutics (NASDAQ:CYTO) entered into an exclusive licensing and distribution agreement with Nuance Pharma for Altamira’s Bentrio nasal spray for protection against airborne viruses and allergens in the...

March 4, 2022

Executive Moves

Graphite Bio names biotech analyst Alethia Young as CFO

Alethia Young Graphite Bio (NASDAQ:GRPH) appointed Alethia Young as CFO, effective April 1, to oversee the company’s finance, investor relations and corporate communications functions, and to play a key role in...

March 4, 2022

Developments

Aravive posts positive updated Phase 1b data in clear cell renal cell carcinoma

Aravive (NASDAQ:ARAV) reported positive new data from the Phase 1b portion of an ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell cancer (ccRCC) and new data from a biomarker high subgroup. Key findings...

March 3, 2022

Markets

SVB Leerink cuts Gemini Therapeutics to MP; PT to $2

SVB Leerink downgraded Gemini Therapeutics (NASDAQ:GMTX) to “market perform” from “outperform” and slashed its price target to $2 from $10, citing an unexpected leadership transition and corporate restructuring. The...

March 3, 2022

Executive Moves

Sigyn Therapeutics names accomplished financial executive Jeremy Ferrell as CFO

Sigyn Therapeutics (OTC:SIGY) appointed Jeremy Ferrell as CFO, effective March 9, 2022, with overall responsibility for operational finance, budgeting, and financial reporting, as well as helping manage Sigyn’s...

March 2, 2022

Markets

Stifel resumes coverage of Rhythm Pharma at buy; PT $23

Stifel resumed coverage of Rhythm Pharmaceuticals (NASDAQ:RYTM) with a “buy” rating and $23 price target. The stock closed at $8.49 on March 1. Rhythm is a commercial biopharmaceutical company developing therapeutics...

March 2, 2022

Markets

Brookline ups CTI Biopharma PT to $12 from $7.20

Brookline Capital Markets raised its price target for CTI Biopharma (NASDAQ:CTIC) to $12 from $7.20 after the FDA approved Vonjo in myelofibrosis. The stock closed at $3.10, up $1.20, on volume of 108 million shares on...

March 1, 2022

Developments

FDA accepts LENSAR 510(k) submission for ALLY

The FDA accepted a 510(k) submission from LENSAR (NASDAQ:LNSR) for its next-generation ALLY Adaptive Cataract Treatment System for substantive review. The submission seeks marketing clearance for the ALLY and is the...

March 1, 2022

Markets

WB starts Arcellx at OP; fair value estimate $40

William Blair initiated coverage of Arcellx (NASDAQ:ACLX) with an “outperform” rating and fair value estimate of $40. The stock closed at $16.94 on Feb. 28. Arcellx’s next-generation cell therapy platform is founded on...

March 1, 2022

Developments

Profound Medical’s TULSA-PRO now compatible with GE Healthcare’s 3T MRI scanners

Profound Medical (NASDAQ:PROF; TSX:PRN) announced the TULSA-PRO system’s new compatibility with GE Healthcare’s 3T Magnetic Resonance Imaging (MRI) scanners. Profound subsequently signed the first site agreement for a...

March 1, 2022

Markets

HCW cuts Celyad Oncology to neutral; removes PT

H.C. Wainwright downgraded Celyad Oncology (NASDAQ:CYAD) to “neutral” from “buy” and removed its price target after the company paused dosing and enrollment in its Phase 1b KEYNOTE-B79 study. Shares of Celyad were...

February 28, 2022

Subscribe